AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7708425 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained paraplegics (TP) in cool climate (15 degrees C)
Number of subjects: 10
Study 7708425 — intervention group
Group type: COMPARATOR
Intervention: Able-bodied subjects (AB) in cool climate (15 degrees C)
Number of subjects: 10
Study 3068399 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase (1,000,000 IU)
Number of subjects: 129
Study 3068399 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 129
Study 31012566 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous heat patch applied for 2 hours per day for 12 weeks
Number of subjects: 15
Study 31012566 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous heat patch
Number of subjects: 15
Study 31012566 — intervention group
Group type: COMPARATOR
Intervention: Untreated wart observation
Number of subjects: 15
Study 28943323 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Anastomosis (PA)
Number of subjects: 102
Study 28943323 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's Procedure (HP)
Number of subjects: 102
Study 26927664 — intervention group
Group type: EXPERIMENTAL
Intervention: Haploidentical donor HSCT (n = 103)
Number of subjects: 210
Study 26927664 — intervention group
Group type: COMPARATOR
Intervention: Matched-sibling donor HSCT (n = 83)
Number of subjects: 210
Study 23299843 — intervention group
Group type: EXPERIMENTAL
Intervention: Community education campaigns, enforcement of environmental regulations, and a wood heater replacement programme to reduce ambient pollution from residential wood stoves started in the winter of 2001.
Number of subjects: 215000
Study 23299843 — intervention group
Group type: COMPARATOR
Intervention: Control group (central Hobart, no specific air quality interventions).
Number of subjects: 215000
Study 21916638 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine FMP2.1/AS02(A)
Number of subjects: 400
Study 21916638 — intervention group
Group type: COMPARATOR
Intervention: Control (rabies vaccine)
Number of subjects: 400
Study 19806414 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program (WP)
Number of subjects: 314
Study 19806414 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking Program plus Pedometer (WPP)
Number of subjects: 314
Study 19806414 — intervention group
Group type: COMPARATOR
Intervention: No Treatment Control (C)
Number of subjects: 314
Study 16625235 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise (20 min at 75% heart rate reserve)
Number of subjects: 16
Study 16625235 — intervention group
Group type: COMPARATOR
Intervention: Control day (no exercise)
Number of subjects: 16
Study 15267121 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal haemorrhoidectomy with radiofrequency bistoury (Group A)
Number of subjects: 31
Study 15267121 — intervention group
Group type: COMPARATOR
Intervention: Diathermic haemorrhoidectomy (Group B)
Number of subjects: 31
Study 11411059 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2 x 850 mg)
Number of subjects: 19
Study 11411059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8677878 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages of 10 to 320 ng/kg/min
Number of subjects: 0
Study 8677878 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages of 40 ng/kg/min
Number of subjects: 0
Study 8677878 — intervention group
Group type: COMPARATOR
Intervention: Propranolol pretreatment
Number of subjects: 0
Study 8677878 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem pretreatment
Number of subjects: 0
Study 8677878 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at dosages > 80 ng/kg/min
Number of subjects: 0
Study 1659913 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopic examination
Number of subjects: 100
Study 1659913 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopic directed biopsies
Number of subjects: 100
Study 6539789 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 msec laser pulses
Number of subjects: 0
Study 6539789 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 msec laser pulses
Number of subjects: 0
Study 6539789 — intervention group
Group type: COMPARATOR
Intervention: Continuous application of the argon laser
Number of subjects: 0
Study 31036542 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-S + GM-CSF (1,000 μg NP-S + 250 μg GM-CSF monthly for 6 months, then every 6 months through 36 months)
Number of subjects: 758
Study 31036542 — intervention group
Group type: COMPARATOR
Intervention: Placebo + GM-CSF (monthly for 6 months, then every 6 months through 36 months)
Number of subjects: 758
Study 31036542 — intervention group
Group type: EXPERIMENTAL
Intervention: NP-S + GM-CSF
Number of subjects: 758
Study 31036542 — intervention group
Group type: COMPARATOR
Intervention: Placebo + GM-CSF
Number of subjects: 758
Study 27768613 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care in high‐risk patients targeted by an Early Warning System
Number of subjects: 206
Study 26118831 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy-randomized intervention with in-depth harm reduction training and additional services (HIV prevention/medical/social service referrals, syringe disposal containers, harm reduction print materials)
Number of subjects: 482
Study 26118831 — intervention group
Group type: COMPARATOR
Intervention: Primary control pharmacies (recruited syringe customers but did not offer additional services)
Number of subjects: 482
Study 26118831 — intervention group
Group type: COMPARATOR
Intervention: Secondary control pharmacies (did not recruit syringe customers)
Number of subjects: 482
Study 23682696 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE intervention (nurse-led home visits)
Number of subjects: 134
Study 23682696 — intervention group
Group type: COMPARATOR
Intervention: Control group (nurse attention during data collection)
Number of subjects: 134
Study 21480266 — intervention group
Group type: EXPERIMENTAL
Intervention: Brown Rice (BR)
Number of subjects: 9
Study 21480266 — intervention group
Group type: COMPARATOR
Intervention: White Rice (WR)
Number of subjects: 9
Study 21480266 — intervention group
Group type: COMPARATOR
Intervention: Polished Brown Rice (PR)
Number of subjects: 9
Study 21480266 — intervention group
Group type: COMPARATOR
Intervention: Glucose Reference (GLU)
Number of subjects: 9
Study 19678966 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with low-carbohydrate diet (CBT-LC)
Number of subjects: 105
Study 19678966 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT with low-fat diet (CBT-LF)
Number of subjects: 105
Study 19678966 — intervention group
Group type: COMPARATOR
Intervention: Control with low-carbohydrate diet (C-LC)
Number of subjects: 105
Study 19678966 — intervention group
Group type: COMPARATOR
Intervention: Control with low-fat diet (C-LF)
Number of subjects: 105
Study 18075937 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumer-operated services (COSPs)
Number of subjects: 0
Study 18075937 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study 15250751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium plus usual care
Number of subjects: 921
Study 15250751 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone (placebo)
Number of subjects: 921
Study 11487161 — intervention group
Group type: EXPERIMENTAL
Intervention: AH-Plus
Number of subjects: 75
Study 11487161 — intervention group
Group type: EXPERIMENTAL
Intervention: Apexit
Number of subjects: 75
Study 11487161 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac-Endo
Number of subjects: 75
Study 11487161 — intervention group
Group type: COMPARATOR
Intervention: Positive Control
Number of subjects: 75
Study 11487161 — intervention group
Group type: COMPARATOR
Intervention: Negative Control
Number of subjects: 75
Study 9772873 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin
Number of subjects: 0
Study 9772873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8631101 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture skill
Number of subjects: 200
Study 8631101 — intervention group
Group type: COMPARATOR
Intervention: Routine suture skill
Number of subjects: 200
Study 2510657 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg o.d.
Number of subjects: 12
Study 2510657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1159434 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulants for an average period of 18 months
Number of subjects: 49
Study 1159434 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment
Number of subjects: 49
Study 30580224 — intervention group
Group type: EXPERIMENTAL
Intervention: TL-eSET (time-lapse monitoring)
Number of subjects: 161
Study 30580224 — intervention group
Group type: COMPARATOR
Intervention: control-eSET (standard evaluation)
Number of subjects: 161
Study 28835271 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 IU vitamin D3 daily
Number of subjects: 172
Study 28835271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 25877802 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc Glycinate (60 mg Zn/day)
Number of subjects: 20
Study 25877802 — intervention group
Group type: COMPARATOR
Intervention: Zinc Gluconate (60 mg Zn/day)
Number of subjects: 20
Study 25877802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 24157649 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based medication management tools alone
Number of subjects: 0
Study 24157649 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR tools plus nurse-led medication therapy management
Number of subjects: 0
Study 24157649 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21748203 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 μg intravaginally every 4 hours (maximum 6 doses)
Number of subjects: 113
Study 21748203 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 113
Study 20201401 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 522
Study 20201401 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic therapy
Number of subjects: 522
Study 20201401 — intervention group
Group type: COMPARATOR
Intervention: Not treated with Cycloferon
Number of subjects: 522
Study 16984719 — intervention group
Group type: EXPERIMENTAL
Intervention: Respect
Number of subjects: 80
Study 16984719 — intervention group
Group type: COMPARATOR
Intervention: Disrespect
Number of subjects: 80
Study 15039146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent bright light (six 15-min bright light pulses of approximately 9,500 lux separated by 60 min of very dim light of <1 lux)
Number of subjects: 21
Study 15039146 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bright light (approximately 9,500 lux)
Number of subjects: 21
Study 15039146 — intervention group
Group type: COMPARATOR
Intervention: Continuous very dim light (<1 lux)
Number of subjects: 21
Study 10953262 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-carotene
Number of subjects: 51000
Study 10953262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 51000
Study 10953262 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 51000
Study 9054792 — intervention group
Group type: EXPERIMENTAL
Intervention: Debriefing intervention 6 months after disaster
Number of subjects: 0
Study 9054792 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 8368410 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac, 75 mg twice daily for 3 to 5 days before and for 7 days after surgery
Number of subjects: 67
Study 8368410 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo preoperatively and diclofenac postoperatively
Number of subjects: 67
Study 8368410 — intervention group
Group type: COMPARATOR
Intervention: Placebo at both times
Number of subjects: 67
Study 8368410 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 67
Study 2872365 — intervention group
Group type: EXPERIMENTAL
Intervention: Linolenic acid (0%, 4%, 8%, 12%, 16% of total energy intake)
Number of subjects: 12
Study 2872365 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (1.7%)
Number of subjects: 12
Study 2872365 — intervention group
Group type: COMPARATOR
Intervention: Control (no linolenic acid or eicosapentaenoic acid)
Number of subjects: 12
Study 29783962 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity category 2 (BMI 35 to < 40)
Number of subjects: 120
Study 29783962 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity category 3 (BMI ≥ 40)
Number of subjects: 120
Study 29783962 — intervention group
Group type: EXPERIMENTAL
Intervention: Not being employed
Number of subjects: 120
Study 29783962 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-English speaking backgrounds
Number of subjects: 120
Study 29783962 — intervention group
Group type: EXPERIMENTAL
Intervention: HLQ domain: ability to actively engage with healthcare providers
Number of subjects: 120
Study 27595147 — intervention group
Group type: EXPERIMENTAL
Intervention: pexacerfont (300 mg/day for 7 days, then 100 mg/day for 21 days)
Number of subjects: 31
Study 27595147 — intervention group
Group type: EXPERIMENTAL
Intervention: pexacerfont
Number of subjects: 31
Study 24503451 — intervention group
Group type: EXPERIMENTAL
Intervention: Video group (BLS learned through videos with on‐screen instructions)
Number of subjects: 128
Study 24503451 — intervention group
Group type: COMPARATOR
Intervention: Picture group (BLS learned by means of pictures combined with written instructions)
Number of subjects: 128
Study 22775294 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 targeted messages
Number of subjects: 181
Study 22775294 — intervention group
Group type: COMPARATOR
Intervention: 10 generic messages
Number of subjects: 181
Study 20390343 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 706
Study 20390343 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 706
Study 18727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipolar RF treatment
Number of subjects: 10
Study 18727024 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar RF treatment
Number of subjects: 10
Study 18727024 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 10
Study 16110017 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hyperfractionated accelerated radiotherapy
Number of subjects: 304
Study 16110017 — intervention group
Group type: COMPARATOR
Intervention: Conventionally fractionated radiotherapy
Number of subjects: 304
Study 12355185 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (300 mg)
Number of subjects: 0
Study 12355185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10030326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (stepwise implementation of behaviour modification, pharmacological therapy targeting hyperglycaemia, hypertension, dyslipidaemia, and microalbuminuria)
Number of subjects: 160
Study 10030326 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment
Number of subjects: 160
Study 10030326 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (followed Danish guidelines)
Number of subjects: 160
Study 7575052 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone alone
Number of subjects: 138
Study 7575052 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel with prednisolone
Number of subjects: 138
Study 7575052 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with prednisolone
Number of subjects: 138
Study 7575052 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment alone (prednisolone)
Number of subjects: 138
Study 2341751 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose human leukocyte interferon-alpha (IFN-alpha)
Number of subjects: 10
Study 7396099 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (i.v. administered)
Number of subjects: 23
Study 31883929 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual tasking (lingual dual task using a smartphone app)
Number of subjects: 37
Study 31883929 — intervention group
Group type: COMPARATOR
Intervention: Recall only (without dual task)
Number of subjects: 37
Study 31042140 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with external attentional focus
Number of subjects: 22
Study 31042140 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with internal attentional focus
Number of subjects: 22
Study 31042140 — intervention group
Group type: COMPARATOR
Intervention: Both groups (internal and external focus)
Number of subjects: 22
Study 28477995 — intervention group
Group type: EXPERIMENTAL
Intervention: Mtwo (VDW, Munich, Germany)
Number of subjects: 65
Study 28477995 — intervention group
Group type: COMPARATOR
Intervention: Reciproc (VDW)
Number of subjects: 65
Study 25918727 — intervention group
Group type: EXPERIMENTAL
Intervention: sulodexide 100 mg/day for 14 weeks
Number of subjects: 20
Study 25918727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23524361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (NaHCO3) only (n = 6; 28 days glucose placebo, acute NaHCO3)
Number of subjects: 24
Study 23524361 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta alanine (BA) and sodium bicarbonate (NaHCO3) (n = 6; 28 days BA, acute NaHCO3)
Number of subjects: 24
Study 23524361 — intervention group
Group type: COMPARATOR
Intervention: Beta alanine (BA) only (n = 6; 28 days BA, acute sodium chloride placebo)
Number of subjects: 24
Study 23524361 — intervention group
Group type: COMPARATOR
Intervention: Placebo only (n = 6; 28 days glucose placebo, acute sodium chloride placebo)
Number of subjects: 24
Study 21414453 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind-Body Bridging (MBB)
Number of subjects: 63
Study 21414453 — intervention group
Group type: COMPARATOR
Intervention: Active sleep education control
Number of subjects: 63
Study 19542797 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcurrent therapy (MCT) patch
Number of subjects: 10
Study 19542797 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 10
Study 17854237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine capsule plus ISDN tablet (V‐HeFT I formulation)
Number of subjects: 19
Study 17854237 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine tablet plus ISDN tablet (V‐HeFT II formulation)
Number of subjects: 19
Study 17854237 — intervention group
Group type: EXPERIMENTAL
Intervention: FDC ISDN/HYD (A‐HeFT formulation)
Number of subjects: 19
Study 15367303 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic pain patients
Number of subjects: 91
Study 15367303 — intervention group
Group type: COMPARATOR
Intervention: Acute pain patients
Number of subjects: 91
Study 15367303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively impaired patients
Number of subjects: 91
Study 15367303 — intervention group
Group type: COMPARATOR
Intervention: Cognitively less-impaired patients
Number of subjects: 91
Study 15367303 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain intensity and improvement in ADL measure
Number of subjects: 91
Study 11543695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate, sulfasalazine, and hydroxychloroquine
Number of subjects: 2221
Study 11543695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of methotrexate and cyclosporin
Number of subjects: 2221
Study 11543695 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of anti-TNF therapy with methotrexate
Number of subjects: 2221
Study 11543695 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids in addition to the combination therapies
Number of subjects: 2221
Study 11543695 — intervention group
Group type: EXPERIMENTAL
Intervention: Other combinations involving parenteral gold, penicillamine, and azathioprine
Number of subjects: 2221
Study 9600553 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular botulinum toxin A (BtA)
Number of subjects: 20
Study 9600553 — intervention group
Group type: COMPARATOR
Intervention: Serial casting
Number of subjects: 20
Study 7973470 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family management with standard dose or targeted medication
Number of subjects: 411
Study 7973470 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational family management
Number of subjects: 411
Study 2681764 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous allopurinol therapy
Number of subjects: 50
Study 2681764 — intervention group
Group type: COMPARATOR
Intervention: Intermittent allopurinol therapy (2 months every year)
Number of subjects: 50
Study 4573357 — intervention group
Group type: EXPERIMENTAL
Intervention: Dip-inoculation slides used in surgery for diagnosis
Number of subjects: 4
Study 4573357 — intervention group
Group type: COMPARATOR
Intervention: Laboratory incubation and interpretation of dip slides
Number of subjects: 4
Study 29446317 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR)
Number of subjects: 19
Study 29446317 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 19
Study 27931951 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-minute withdrawal
Number of subjects: 200
Study 27931951 — intervention group
Group type: COMPARATOR
Intervention: 6-minute withdrawal
Number of subjects: 200
Study 26502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Low Frequency Shock Wave (LFSW)
Number of subjects: 120
Study 26502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + Medium Frequency Shock Wave (MFSW)
Number of subjects: 120
Study 26502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture + High Frequency Shock Wave (HFSW)
Number of subjects: 120
Study 26502544 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Acupuncture
Number of subjects: 120
Study 23951832 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention program (2 days duration)
Number of subjects: 226
Study 21513477 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet-rich fibrin (PRF) with open-flap debridement
Number of subjects: 56
Study 21513477 — intervention group
Group type: COMPARATOR
Intervention: Open-flap debridement alone
Number of subjects: 56